<DOC>
	<DOCNO>NCT00475371</DOCNO>
	<brief_summary>26 subject enrol 5 different dose group . The trial consist screening , dose follow-up visit . Dosing visit 2 , MKC253 Inhalation Powder , Glucagon-Like Peptide-1 ( GLP-1 ) give 5 dose level .</brief_summary>
	<brief_title>A First Human , Single Dose , Safety Tolerability Study MKC253 Inhalation Powder Healthy Adult Males</brief_title>
	<detailed_description>This Phase 1a , single-dose trial incorporate open-label , ascend dose strategy determine safety &amp; tolerability MKC253 ( GLP1/TechnosphereÂ® ) Inhalation Powder . The trial consist screen , dose follow-up visit . Single dose administration MKC253 occur dose visit . Five dos assess : 0.05 , 0.45 , 0.75 , 1.05 &amp; 1.5 mg GLP-1 . Dosing ascend cohort occur Principal Investigator review safety/tolerability data</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Healthy male = 18 = 45 year age Written Informed Consent . Body Mass Index ( BMI ) &lt; 30 kg/m2 Nonsmoker Normal pulmonary function performance pulmonary function test Clinically significant disease include diabetes mellitus Fasting blood glucose &gt; 110 mg/dL ( 6.1 mmol/L ) Significant psychiatric condition drug alcohol abuse Any condition , opinion PI , make subject unsuitable clinical trial , could limit validity inform consent and/or impair subject 's ability participate trial Inability perform PFT maneuver meet recommended American Thoracic Society ( ATS ) standard acceptability repeatability criterion</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Diabetes Mellitus : Type II</keyword>
</DOC>